Synthesis and evaluation of multisubstrate bicyclic pyrimidine nucleoside inhibitors of human thymidine phosphorylase

Journal of Medicinal Chemistry

Volumn 49, Issue 26, 2006, Pages 7807-7815

  Allan, Amy L ^a   Gladstone, Patricia L ^a   Price, Melissa L P ^a   Hopkins, Stephanie A ^a   Juarez, Jose C ^a   Doñate, Fernando ^a   Ternansky, Robert J ^a   Shaw, David E ^b,c   Ganem, Bruce ^d   Li, Yingbo ^d   Wang, Weiru ^d   Ealick, Steven ^d  

^a Attenuon LLC   (United States)

^b D E SHAW RESEARCH   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d Department of Obstetrics Gynecology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 6 [1 (2 AMINOPYRROLIDINYL)METHYL]URACIL; BICYCLO COMPOUND; ENZYME INHIBITOR; PHOSPHONIC ACID DERIVATIVE; PYRIMIDINE NUCLEOSIDE; THYMIDINE PHOSPHORYLASE; THYMIDINE PHOSPHORYLASE INHIBITOR; UNCLASSIFIED DRUG; URACIL DERIVATIVE;

ARTICLE; COMPLEX FORMATION; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; MOLECULAR MODEL; STEREOCHEMISTRY;

BICYCLO COMPOUNDS, HETEROCYCLIC; ENZYME INHIBITORS; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PYRIMIDINE NUCLEOSIDES; STRUCTURE-ACTIVITY RELATIONSHIP; THYMIDINE PHOSPHORYLASE;

EID: 33845944644     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060428u     Document Type: Article

References (56)

1. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971, 285, 1182-1186.
2. Folkman, J. Tumor Angiogenesis. In Cancer Medicine, 4th ed.; Holland, J. F., Bast, R. C., Morton, D. L., Frei, E., Kufe, D. W., Weichselbaum, R. R., Eds.: Williams & Wilkens: Baltimore, MD, 1996; Vol. 1, pp 181-204.
3. Folkman, J. What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst. 1990, 82, 4-6.
4. Matter, A. Tumor angiogenesis as a therapeutic target. Drug Discovery Today 2001, 6, 1005-1024.
5. Cristofanilli, M.; Charasangavej, C.; Hortobagyi, G. N. Angiogenesis modulation in cancer research: Novel clinical approaches. Nat. Rev. 2002, 1, 415-426.
6. Davis, D. W.; McConkey, D. J.; Zhang, W.; Herbst, R. S. Antiangiogenic tumor therapy. BioTechniques 2003, 34, 1048-1063.
7. Cole, C.; Foster, A. J.; Freeman, S.; Jaffar, M.; Murray, P. E.; Stratford, I. J. The role of thymidine phosphorylase/PD-ECGF in cancer chemotherapy: a chemical perspective. Anti-Cancer Drug Des. 1999, 14, 383-392.
8. Griffiths, L.; Stratford, I. J. Platelet-derived endothelial cell growth factor thymidine phosphorylase in tumor growth and response to therapy. Br. J. Cancer 1997, 76, 689-693.
9. Folkman, J. What is the role of thymidine phosphorylase in tumor angiogenesis? J. Natl. Cancer Inst. 1996, 88, 1091-1092.
10. Perez-Perez, M. J.; Priego, E. M.; Hernandez, A. I.; Camarasa, M. J.; Balzarini, J.; Liekens, S. Thymidine phosphorylase inhibitors: recent developments and potential therapeutic applications. Mini-Rev. Med. Chem. 2005, 12, 1113-1123.
11. Moghaddam, A.; Bicknell, R. Expression of platelet-derived endothelial cell growth factor in Escherichia coli and confirmation of its thymidine phosphorylase activity. Biochemistry 1992, 31, 12141-12146.
12. Furukawa, T.; Yoshimura, A.; Sumizawa, T.; Haraguchi, M.; Akiyama, S.; Fukui, K.; Ishizawa, M.; Yamada, Y. Angiogenic factor. Nature 1992, 356, 668-668.
13. Brown, N. S.; Jones, A.; Fujiyama, C.; Harris, A. L.; Bicknell, R. Thymidine phosphorylase induces carcinoma cell oxidative stress and promotes secretion of angiogenic factors. Cancer Res. 2000, 60, 6298-6302.
14. Usuki, K.; Saras, J.; Waltenberger, J.; Miyazono, K.; Pierce, G.; Thomason, A.; Heldin, C. H. Platelet-derived endothelial cell growth factor has thymidine phosphorylase activity. Biochem. Biophys. Res. Commun. 1992, 184, 1311-1316.
15. Ishikawa, F.; Miyazono, K.; Hellman, U.; Drexler, H.; Wernstedt, C.; Hagiwara, K.; Usuki, K.; Takaku, F.; Risau, W.; Heldin, C. H. Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature 1989, 338, 557-562.
16. Haraguchi, M.; Miyadera, K.; Uemura, K.; Sumizawa, T.; Furukawa, T.; Yamada, K.; Akiyama, S.; Yamada, Y. Angiogenic activity of enzymes. Nature 1994, 368, 198.
17. Moghaddam, A.; Zhang, H. T.; Fan, T. P. D.; Hu, D. E.; Lees, V.; Turley, H.; Fox, S. B.; Gatter, K. C.; Harris, A. L.; Bicknell, R. Thymidine phosphorylase is angiogenic and promotes tumor-growth. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 998-1002.
18. Matsushita, S.; Nitanda, T.; Furukawa, T.; Sumizawa, T.; Tani, A.; Nishimoto, K.; Akiba, S.; Miyadera, K.; Fukushima, M.; Yamada, Y.; Yoshida, H.; Kanzaki, T.; Akiyama, S. The effect of a thymidine phosphorylase inhibitor on angiogenesis and apoptosis in tumors. Cancer Res. 1999, 59, 1911-1916.
19. Focher, F.; Spadari, S. Thymidine phosphorylase: a two-face Janus in anticancer chemotherapy. Curr. Cancer Drug Targets 2001, 1, 141-153.
20. Takeuchi, M.; Otsuka, T.; Matsui, N.; Asai, K.; Hirano, T.; Moriyama, A.; Isobe, I.; Eksioglu, Y. Z.; Matsukawa, K.; Kato, T. Aberrant production of gliostatin/platelet-derived endothelial cell growth factor in rheumatoid synovium. Arthritis Rheum. 1994, 37, 662-672.
21. Creamer, D.; Jaggar, R.; Allen, M.; Bicknell, R.; Barker, J. Overexpression of the angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase in psoriatic epidermis. Br. J. Dermatol. 1997, 137, 851-855.
22. Iltzsch, M. H.; el Kouni, M. H.; Cha, S. Kinetic studies of thymidine phosphorylase from mouse liver. Biochemistry 1985, 24, 6799-6807.
23. Friedkin, M.; Roberts, D. The enzymatic synthesis of nucleosides. I. Thymidine phosphorylase in mammalian tissue. J. Biol. Chem. 1954, 207, 245-256.
24. Desgranges, C.; Razaka, G.; Rabaud, M.; Bricaud, H.; Balzarini, J.; DeClercq, E. Phosphorolysis of (E)-5-(2-bromovinyl)-2′-deoxyuridine (BVDU) and other 5-substituted-2′-deoxyuridines by purified human thymidine phosphorylase and intact blood platelets. Biochem. Pharmacol. 1983, 32, 3583-3590.
25. Pugmire, M. J.; Ealick, S. E. The crystal structure of pyrimidine nucleoside phosphorylase in a closed conformation. Structure 1998, 6, 1467-1479.
26. Pugmire, M. J.; Cook, W. J.; Jasanoff, A.; Walter, M. R.; Ealick, S. E. Structural and theoretical studies suggest domain movement produces an active conformation of thymidine phosphorylase. J. Mol. Biol. 1998, 281, 285-299.
27. Walter, M. R.; Cook, W. J.; Cole, L. B.; Short, S. A.; Koszalka, G. W.; Krenitsky, T. A.; Ealick, S. E. Three-dimensional structure of thymidine phosphorylase from Escherichia coli at 2.8 Å resolution. J. Biol. Chem. 1990, 265, 14016-14022.
28. Erion, M. D.; Stoeckler, J. D.; Guida, W. C.; Walter, R. L.; Ealick, S. E. Purine nucleoside phosphorylase. 2. Catalytic mechanism. Biochemistry 1997, 36, 11735-11748.
29. Koellner, G.; Bzowska, A.; Wielgus-Kutrowska, B.; Luic, M.; Steiner, T.; Saenger, W.; Stepinski, J. Open and closed conformation of the E. coli purine nucleoside phosphorylase active center and implications for the catalytic mechanism. J. Mol. Biol. 2002, 315, 351-371.
30. Birck, M. R.; Schramm, V. L. Nucleophilic participation in the transition state for human thymidine phosphorylase. J. Am. Chem. Soc. 2004, 126, 2447-2453.
31. Niedzwicki, J. G.; el Kouni, M. H.; Chu, S. H.; Cha, S. Structure-activity relationship of ligands of the pyrimidine nucleoside phosphorylases. Biochem. Pharmacol. 1983, 32, 399-415.
32. Grancharov, K.; Mladenova, J.; Golovinsky, E. Inhibition of uridine phosphorylase by some pyrimidine derivatives. Biochem. Pharmacol. 1991, 41, 1769-1772.
33. Focher, F.; Ubiali, D.; Pregnolato, M.; Zhi, C.; Gambino, J.; Wright, G. E.; Spadari, S. Novel nonsubstrate inhibitors of human thymidine phosphorylase, a potential target for tumor-dependent angiogenesis. J. Med. Chem. 2000, 43, 2601-2607.
34. Murray, P. E.; McNally, V. A.; Lockyer, S. D.; Williams, K. J.; Stratford, I. J.; Jaffar, M.; Freeman, S. Synthesis and enzymatic evaluation of pyridinium-substituted uracil derivatives as novel inhibitors of thymidine phosphorylase. Bioorg. Med. Chem. Lett. 2002, 10, 525-530.
35. Cole, C.; Reigan, P.; Gbaj, A.; Edwards, P. N.; Douglas, K. T.; Stratford, I. J.; Freeman, S.; Jaffar, M. Potential tumor-selective nitroimidazolylmethyluracil prodrug derivatives: inhibitors of the angiogenic enzyme thymidine phosphorylase. J. Med. Chem. 2004, 36, 207-209.
36. Langen, P.; Etzold, G.; Bärwolff, D.; Preussel, B. Inhibition of thymidine phosphorylase by 6-aminothymine and derivatives of 6-aminouracil. Biochem. Pharmacol. 1967, 16, 1833-1837.
37. Klein, R. S.; Lenzi, M.; Lim, T. H.; Hotchkiss, K. A.; Wilson, P.; Schwartz, E. L. Novel 6-substituted uracil analogs as inhibitors of the angiogenic actions of thymidine phosphorylase. Biochem. Pharmacol. 2001, 62, 1257-1263.
38. Woodman, P. W.; Sarrif, A. M.; Heidelberger, C. Inhibition of nucleoside phosphorylase cleavage of 5-fluoro-2′-deoxyuridine by 2,4-pyrimidinedione derivatives. Biochem. Pharmacol. 1980, 29, 1059-1063.
39. Price, M. L.; Guida, W. C.; Jackson, T. E.; Nydick, J. A.; Gladstone, P. L.; Juarez, J. C.; Doñate, F.; Ternansky, R. J. Design of novel N-(2,4-dioxo-1,2,3,4-tetrahydrothieno[3,2-d]pyrimidin-7-yl)-guanidines as thymidine phosphorylase inhibitors, and flexible docking to a homology model. Bioorg. Med. Chem. Lett. 2003, 13, 107-110.
40. Hirota, K.; Sawada, M.; Sajiki, H.; Sako, M. Synthesis of 6-amino-uracils and pyrrolo[2,3-d]pyrimidine-2,4-diones and their inhibitory effect on thymidine phosphorylase. Nucleic Acids Symp. Ser. 1997, 37, 59-60.
41. Fukushima, M.; Suzuki, N.; Emura, T.; Yano, S.; Kazuno, H.; Tada, Y.; Yamada, Y.; Asao, T. Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2′- deoxyribonucleosides. Biochem. Pharmacol. 2000, 59, 1227-1236.
42. Yano, S.; Tada, Y.; Kuzuno, H.; Suto, T.; Tamashita, J.; Suzuki, N.; Emura, T.; Fukushima, M.; Asao, T. Int. Patent Appl. WO96/3034, 1996.
43. Thomas, M. B.; Hoff, P. M.; Carter, S.; Bland, G.; Lassere, Y.; Wolff, R.; Xiong, H.; Hayakawa, T.; Abbruzzese, J. A dose-finding, safety and pharmacokinetics study of TAS-102, an antitumor/antiangiogenic agent given orally on a once-daily schedule for five-days every three weeks in patients with solid tumors. Proc. Am. Assoc. Cancer Res. 2002, 43, 554.
44. Yano, S.; Kazuno, H.; Sato, T.; Suzuki, N.; Emura, T.; Wierzba, K.; Yamashita, J.; Tada, Y.; Yamada, Y.; Fukushima, M.; Asao, T. Synthesis and evaluation of 6-methylene-bridged uracil derivatives. Part 2: Optimization of inhibitors of human thymidine phosphorylase and their selectivity with uridine phosphorylase. Bioorg. Med. Chem. 2004, 12, 3443-3450.
45. Reigan, P.; Edwards, P. N.; Gbaj, A.; Cole, C.; Barry, S. T.; Page, K. M.; Ashton, S. E.; Luke, R. W. A.; Douglas, K. T.; Stratford, I. J.; Jaffar, M.; Bryce, R. A.; Freeman, S. Aminoimidazolylmethyluracil analogues as potent inhibitors of thymidine phosphorylase and their bioreductive nitroimidazolyl prodrugs. J. Med. Chem. 2005, 48, 392-402.
46. Balzarini, J.; Degrève, B.; Esteban-Gamboa, A.; Esnouf, R.; De Clercq, E.; Engelborghs, Y.; Camarasa, M.-J.; Pérez-Pérez, M.-J. Kinetic analysis of novel multisubstrate analogue inhibitors of thymidine phosphorylase. FEBS Lett. 2000, 483, 181-185.
47. Esteban-Gamboa, A.; Balzarini, J.; Esnouf, R.; De Clercq, E.; Camarasa, M.-J.; Pérez-Pérez, M.-J. Design, synthesis and enzymatic evaluation of multisubstrate analogue inhibitors of Escherichia coli thymidine phosphorylase. J. Med. Chem. 2000, 43, 971-983.
48. Li, Y. Studies in Nucleoside Chemistry. Synthesis of Purine and Pyrimidine Nucleoside Phosphorylase Inhibitors. Total Synthesis of the Sulfated Nulceoside Glycoside HF-7. Ph.D. Dissertation, Cornell University, Ithaca, NY, January 2000.
49. Wataya, Y.; Santi, D. W. Continuous spectrophotometric assay of thymidine phosphorylase using 5-nitro-2′-deoxyuridine as substrate. Anal. Biochem. 1981, 112, 96-98.
50. Noronha, A. M.; Wilds, C. J.; Lok, C-N.; Viazovkina, K.; Arion, D.; Parniak, M. A.; Damha, M. J. Synthesis and biophysical properties of arabinonucleic acids (ANA): circular dichroic spectra, melting temperatures, and ribonuclease H susceptibility of ANA·RNA hybrid duplexes. Biochemistry 2000, 39, 7050-7062.
51. Lewis, A. F.; Revankar, G. R. 2′-O,5-Dimethyluridine: a total synthesis and single crystal X-ray diffraction study. J. Heterocycl. Chem. 1993, 30, 1309-1315.
52. 2,3-Etheno-2′-deoxyguanosine[8,9-dihydro-9-oxo-2′-deoxy- 3-β-D-ribofuranosylimidazo[2,1-b]purine]: a practical synthesis and characterization. J. Org. Chem. 1993, 58, 2552-2556.
53. De Mesmaeker, A.; Lebreton, J.; Hoffman, P.; Freier, S. M. Stereocontrolled synthesis of 2′-α-C-branched nucleoside analogues and their incorporation into oligodeoxyribonucleotides. Synlett 1993, 677-679.
54. Furusawa, K.; Ueno, K.; Katsura, T. Synthesis and restricted conformation of 3′,5′-O-(di-t-butylsilanediyl)ribonulceosides. Chem. Lett. 1990, 97-100.
55. Jorgensen, W. L.; Maxwell, D. S.; Tirado-Rives, J. Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J. Am. Chem. Soc. 1996, 118, 11225-11236.
56. Mohamadi, F.; Richards, N. G. J.; Guida, W. C.; Liskamp, R.; Lipton, M.; Caufield, C.; Chang, G.; Hendrickson, T.; Still, W. C. Macromodel, an integrated software system for modeling organic and bioorganic molecules using molecular mechanics. J. Comput. Chem. 1990, 11, 440.